MAX Surgical Specialty welcomes Brian Lawson as SVP of business development

MAX Surgical Specialty Management recently welcomed Brian Lawson as the new senior vice president of business development. With a 15-year legacy of success in strategy, growth and mergers & acquisitions across the health care industry, Lawson’s arrival marks a significant milestone for MAX as it redefines and elevates the delivery of services and support to leading oral and maxillofacial surgical practices.

“MAX’s growth and evolution have always been driven by the talent, enthusiasm and experience of the people we bring on board,” Dr. Jason Auerbach, founder of Riverside Oral Surgery, said. “Brian brings with him a proven track record in business development. I’m excited to collaborate with him and the rest of the MAX team as we continue to build an outstanding company that redefines the role of specialty health care management.”

Riverside Oral Surgery was started in 2007 by Auerbach when he began to realize his vision of providing the optimal patient experience through clinical excellence, compassionate care and close attention to every detail. Auerbach now leads MAX Surgical Specialty Management LLC, the leading disruptor in surgeon-led OMS platforms. MAX is changing the landscape for what was known possible to private practice owners, supporting 28 surgeons in four states across the Northeast.

Before joining MAX, Lawson served as chief development officer at SALT Dental Collective, where he spearheaded the firm’s explosive growth from 18 locations in two states to an impressive 100 locations in 10 states. His leadership in business development at Covenant Physician Partners and SAGE Veterinary Centers, coupled with his investment banking expertise at Harris Williams & Co., further cement his reputation as a transformative leader.

Auerbach and co-CEO Mark Censoprano share a unified vision for the future of MAX, and Lawson is the newest addition to help advance that mission.

“Brian’s experience and expertise are a tremendous value to our team,” Censoprano said. “I look forward to working closely with him to further strengthen MAX’s growth and enhance our support to our surgeons.”